Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma
NCT07191379Phase 4Not yet recruiting
- Sponsor
- University Hospital Odense
- Start
- Nov 2026
- Primary completion
- Jun 2027
01
Overview
A Phase 4 trial of daratumumab in multiple myeloma (MM), sponsored by University Hospital Odense. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07191379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07191379.